MC4R: Melanocortin receptor 4
G protein-coupled receptor that binds melanocyte-stimulating hormones (alpha- and beta-MSH) and corticotropin/ACTH, which are peptide products of the POMC precursor.
- Drugs that act on it: 3
- Approved: 2
- In phases 1 to 3: 1
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on MC4R, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
- Protein or peptide 2
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Melanocortin receptor 4 agonist.| Setmelanotide | Approved | Rhythm Pharmaceuticals | Protein or peptide | Agonist | 5 |
| Bremelanotide | Approved | Cosette Pharmaceuticals | Protein or peptide | Agonist | 1 |
| PF-00446687 | Phase 2 | Pfizer | Small molecule | Agonist | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.| Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity | Setmelanotide | Phase 4 | Recruiting | Tom Hühne | Jun 29, 2026 |
| Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | Setmelanotide | Phase 2 | Enrolling by invitation | Massachusetts General Hospital | Mar 27, 2026 |
| A Study of Setmelanotide in Patients With Prader-Willi Syndrome | Setmelanotide | Phase 2 | Active, not recruiting | Rhythm Pharmaceuticals, Inc. | Jan 13, 2025 |
| A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | Setmelanotide | Phase 3 | Recruiting | Rhythm Pharmaceuticals, Inc. | Jan 7, 2025 |
| A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | Bremelanotide | Phase 2 | Active, not recruiting | Palatin Technologies, Inc | Aug 22, 2024 |
| A Trial of Setmelanotide in Acquired Hypothalamic Obesity | Setmelanotide | Phase 3 | Active, not recruiting | Rhythm Pharmaceuticals, Inc. | Mar 20, 2023 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Obesity disorder
- 0.82
- Abnormality of the skeletal system
- 0.73
- Obesity due to melanocortin 4 receptor deficiency
- 0.69
- Sexual dysfunction
- 0.49
- Bardet-Biedl syndrome
- 0.48
- Type 2 diabetes mellitus
- 0.47
- Inherited obesity
- 0.41
- Overnutrition
- 0.40
- Monogenic diabetes
- 0.40
- Dentures
- 0.39
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL259, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P32245, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets